Unmanipulated HLA 2-3 antigen–mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis
- 31 January 2008
- journal article
- clinical trial
- Published by Elsevier BV in Experimental Hematology
- Vol. 36 (1), 1-8
- https://doi.org/10.1016/j.exphem.2007.08.013
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Full Haplotype-Mismatched Hematopoietic Stem-Cell Transplantation: A Phase II Study in Patients With Acute Leukemia at High Risk of RelapseJournal of Clinical Oncology, 2005
- Graft engineering for allogeneic haploidentical stem cell transplantationBlood Cells, Molecules, and Diseases, 2004
- Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantationTransplantation, 2002
- Treatment of High-Risk Acute Leukemia with T-Cell–Depleted Stem Cells from Related Donors with One Fully Mismatched HLA HaplotypeNew England Journal of Medicine, 1998
- Use of Partially Mismatched Related Donors Extends Access to Allogeneic Marrow TransplantBlood, 1997
- Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donorsTransfusion Science, 1994
- Bone Marrow TransplantationNew England Journal of Medicine, 1994
- Marrow Transplantation from Related Donors Other Than HLA-Identical SiblingsNew England Journal of Medicine, 1985
- Chronic graft-versus-host syndrome in manAmerican Journal Of Medicine, 1980
- CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,STransplantation, 1974